Therapeutic Variables in Cataract Surgery | NCT00407017

Studies
Therapeutic Variables in Cataract Surgery

NCT00407017

Sponsor

Innovative Medical

Status

Completed

Last Update Posted

Aug 21, 2007Estimated

Enrollment

Not provided

Phase

Phase 4

Conditions

Cataract Surgery

Interventions

Gatifloxacin
Ketorolac LS
Pred Forte
Moxifloxacin
Nepafenac
EconoPred Plus

Countries

United States

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Aug 2007

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Not provided

Primary Completion Date

Not provided

Completion Date

Not provided

First Submitted Date

Nov 30, 2006

First Submission Date that Met QC Criteria

Dec 1, 2006

First Posted Date

Dec 4, 2006Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Aug 17, 2007

Last Update Posted Date

Aug 21, 2007Estimated

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Phase 4

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Males or females scheduled to undergo cataract surgery
Patients can be receiving monofocal IOLs only
Likely to complete all study visits and able to provide informed consent
Visual potential of 20/25 or better

Exclusion Criteria:

Known contraindications to any study medication or ingredients
Active ocular diseases or uncontrolled systemic disease
Active ocular allergies

Accepts Healthy Volunteers

Not provided

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

Not provided

Maximum Age

Not provided

Standard Ages

ChildAdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Name	Affiliation	Role
William Trattler, MD	The Center For Excellence in Eye Care	Principal Investigator

Locations

Facility	Status	City	State	ZIP	Country	Contacts
The Center for Excellence in Eye Care		Miami	Florida	33176	United States

Intervention Browse Module

MeSH Terms

ID	Term
D000077734	Gatifloxacin
C009935	prednisolone acetate
D000077266	Moxifloxacin
C414203	nepafenac
D008775	Methylprednisolone

Ancestor Terms

ID	Term
D024841	Fluoroquinolones
D042462	4-Quinolones
D015363	Quinolones
D011804	Quinolines

Browse Leaves

Not provided

Browse Branches

Not provided

Name	Type	Description	Arm Group Labels	Other Names
Gatifloxacin	Drug
Ketorolac LS	Drug
Pred Forte	Drug
Moxifloxacin	Drug
Nepafenac	Drug
EconoPred Plus	Drug